HUP0300480A2 - 2-Acil-indol-származékok és tumorellenes szerként történő alkalmazásuk - Google Patents
2-Acil-indol-származékok és tumorellenes szerként történő alkalmazásukInfo
- Publication number
- HUP0300480A2 HUP0300480A2 HU0300480A HUP0300480A HUP0300480A2 HU P0300480 A2 HUP0300480 A2 HU P0300480A2 HU 0300480 A HU0300480 A HU 0300480A HU P0300480 A HUP0300480 A HU P0300480A HU P0300480 A2 HUP0300480 A2 HU P0300480A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- atom
- substituted
- group
- chain
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000005843 halogen group Chemical group 0.000 abstract 6
- -1 acetyl- Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- 239000003574 free electron Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 abstract 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical class 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgyát új, (I) általános képletű indol- ésheteroindolszármazékok, tautomer- és sztereoizomerformáik, ezekkeverékei és gyógyászatilag elfogadható sóik képezik. A találmánytovábbá a fenti vegyületek előállítására és az (I) általános képletűindolszármazékok gyógyszerként történő alkalmazására is vonatkozik. Az(I) általános képletben R1 jelentése hidrogénatom, (C1-C6)-alkil-karbonil-, előnyösen acetil-, (C1-C6)-alkil-, mono-(C1-C6)-alkil-amino-(C1-C4)-alkil-, di(C1-C6)-alkil-amino-(C1-C4)-alkilcsoport, ahola két (C1-C6)- alkil-csoport együtt egy gyűrűt képezhet, amely adottesetben egy vagy több NH, N-(C1-C6)-alkilcsoportot, O vagy S atomot,(C6-C14)-aril-(C1-C6)-alkil- vagy (C6-C14)-aril-(C1-C6)-alkoxi-(C1-C6)-alkil-csoportot tartalmaz; R2 jelentése hidrogénatom, halogénatom,ciano-, nitro-, (C1-C6)-alkil-, egy vagy több halogénatommal,előnyösen trifluor-metil-csoporttal szubsztituált (C1-C6)-alkil-, egyvagy több halogénatommal, előnyösen trifluor-metoxi-csoporttalszubsztituált (C1-C6)-alkoxi-, (C2-C6)-alkenil-, (C2-C6)-alkinil-,(C3-C8)-cikloalkil-, (C1-C6)-alkoxi-karbonil-oxi-, (C1-C6)-alkil-karbonil-oxi-, (C1-C4)-alkil-tio-, (C1-C4)-alkil-szulfinil-, (C1-C4)-alkil-szulfonil-, (C1-C6)-alkoxi-(C1-C6)-alkil-, amino-, mono-(C1-C6)-alkil-amino-, di-N,N-(C1-C6)-alkil-amino-csoport; A, B, C és Djelentése egymástól függetlenül nitrogénatom (mely esetben R3, R4, R5és R6 jelentése a nitrogénatom szabad elektronpárja) vagy az R3-R6-csoport egyikével szubsztituált szénatom; R3, R4, R5 és R6 jelentéseegymástól függetlenül, amikor nitrogén- atomhoz kapcsolódik egy szabadelektronpár, vagy amikor szénatomhoz kapcsolódik, hidrogénatom,halogénatom, ciano-, nitro-, egyenes vagy elágazó láncú (C1-C6)-alkil-, egy vagy több halogénatommal, előnyösen trifluor-metil-csoporttal szubsztituált egyenes vagy elágazó láncú (C1-C6) -alkil-,egy vagy több halogénatommal, előnyösen trifluor-metoxicsoporttalszubsztituált egyenes vagy elágazó láncú (C1-C6)-alkoxi-, (C2-C6)-alkenil-, (C2-C6)-alkinil-, (C3-C8)- X jelentése oxigén- vagy kénatom,NH vagy geminálisan (ugyanazon szénatomon) szubsztituálthidroxilcsoport és hidrogénatom (-CH(OH)-); Y jelentéseszubsztituálatlan (C6-C14)-aril- vagy teljesen vagy részlegesen,azonos vagy különböző szubsztituensekkel, előnyösen fenil- vagy 1-vagy 2-naftilcsoporttal szubsztituált (C6-C14)-arilcsoport, vagyszubsztituálatlan (C1-C13)-heteroaril- vagy azonos vagy különbözőszubsztituensekkel teljesen vagy részlegesen szubsztituált és mindenesetben legalább 1-4 N, NH, N-(C1-C6)-alkilcsoportot, O és/vagy Satomot, mint gyűrűatomot tartalmazó (C1-C13)-heteroaril-csoport. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2000120852 DE10020852A1 (de) | 2000-04-28 | 2000-04-28 | 2-Acryl-indolderivate und deren Verwendung als Antitumormittel |
| DE2001102629 DE10102629A1 (de) | 2001-01-20 | 2001-01-20 | 2-Acyl-indolderivate und deren Verwendung als Antitumormittel |
| PCT/EP2001/004783 WO2001082909A2 (de) | 2000-04-28 | 2001-04-27 | 2-acyl-indolderivate und deren verwendung als antitumormittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0300480A2 true HUP0300480A2 (hu) | 2003-06-28 |
| HUP0300480A3 HUP0300480A3 (en) | 2006-04-28 |
Family
ID=26005501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0300480A HUP0300480A3 (en) | 2000-04-28 | 2001-04-27 | 2-acyl indol derivatives and their use as anti-tumour agents |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20020091124A1 (hu) |
| EP (1) | EP1276720B1 (hu) |
| JP (1) | JP2004501092A (hu) |
| KR (1) | KR20030024661A (hu) |
| CN (1) | CN1286810C (hu) |
| AR (1) | AR029915A1 (hu) |
| AT (1) | ATE348805T1 (hu) |
| AU (1) | AU783459B2 (hu) |
| BG (1) | BG107309A (hu) |
| BR (1) | BR0110414A (hu) |
| CA (1) | CA2407677A1 (hu) |
| CZ (1) | CZ20023544A3 (hu) |
| DE (1) | DE50111690D1 (hu) |
| EE (1) | EE200200607A (hu) |
| GE (1) | GEP20063751B (hu) |
| HK (1) | HK1054549B (hu) |
| HR (1) | HRP20020940A2 (hu) |
| HU (1) | HUP0300480A3 (hu) |
| IL (1) | IL152477A0 (hu) |
| IS (1) | IS6594A (hu) |
| MX (1) | MXPA02010627A (hu) |
| NO (1) | NO20025150L (hu) |
| NZ (1) | NZ522246A (hu) |
| PL (1) | PL358877A1 (hu) |
| RU (1) | RU2002132253A (hu) |
| SK (1) | SK15432002A3 (hu) |
| WO (1) | WO2001082909A2 (hu) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
| DE10152306A1 (de) * | 2001-10-26 | 2003-07-24 | Asta Medica Ag | 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften |
| AU2003214462A1 (en) | 2002-04-03 | 2003-10-13 | Astrazeneca Ab | Indole derivatives having anti-angiogenetic activity |
| UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
| TW200400177A (en) | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| SE0300908D0 (sv) * | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
| AU2004297235A1 (en) * | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| PE20060430A1 (es) | 2004-06-09 | 2006-05-25 | Glaxo Group Ltd | Derivados de pirrolopiridina como moduladores de los receptores cannabinoides |
| CA2580221A1 (en) * | 2004-10-05 | 2006-04-13 | Merz Pharma Gmbh & Co. Kgaa | Novel cyclic and acyclic propenones for treating cns disorders |
| NZ556686A (en) * | 2005-02-14 | 2010-01-29 | Bionomics Ltd | Novel tubulin polymerisation inhibitors |
| US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| KR20080087070A (ko) * | 2005-05-20 | 2008-09-30 | 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 | 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제 |
| US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
| FR2950053B1 (fr) * | 2009-09-11 | 2014-08-01 | Fournier Lab Sa | Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
| WO2014033497A1 (en) | 2012-08-27 | 2014-03-06 | Centre National De La Recherche Scientifique | 5-azaindole compounds with anticancer and antiangiogenic activities |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| EP2972394A4 (en) | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | HSP90 TARGETING CARDIAC IMAGING AND TREATMENT THEREOF |
| JP6820854B2 (ja) * | 2015-01-18 | 2021-01-27 | エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ | Ｍａｐ４ｋ４（ｈｇｋ）インヒビター |
| CN104945376B (zh) * | 2015-07-09 | 2017-03-15 | 安徽理工大学 | 一种3‑芳酰基吲哚化合物的合成方法 |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| CN107722013B (zh) * | 2016-08-11 | 2021-01-12 | 中国科学院上海药物研究所 | 去氮嘌呤类化合物及其药物组合物、制备方法和用途 |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3660430A (en) * | 1969-11-04 | 1972-05-02 | American Home Prod | 2-substituted-3-arylindoles |
| US3838167A (en) * | 1972-08-01 | 1974-09-24 | Lilly Co Eli | Process for preparing indoles |
| DK3375A (hu) * | 1974-01-25 | 1975-09-15 | Ciba Geigy Ag | |
| US5436265A (en) * | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
| NZ334344A (en) * | 1996-09-12 | 2000-08-25 | Cancer Res Campaign Tech | benzo[e]indole and pyrrolo[3,2-e]indole compounds and their use as prodrugs |
| AP9801302A0 (en) * | 1997-07-23 | 2000-01-23 | Pfizer | Indole compounds as anti-inflammatory/analgesic agents.. |
-
2001
- 2001-04-27 DE DE50111690T patent/DE50111690D1/de not_active Expired - Fee Related
- 2001-04-27 EE EEP200200607A patent/EE200200607A/xx unknown
- 2001-04-27 HU HU0300480A patent/HUP0300480A3/hu unknown
- 2001-04-27 KR KR1020027014523A patent/KR20030024661A/ko not_active Application Discontinuation
- 2001-04-27 CA CA002407677A patent/CA2407677A1/en not_active Abandoned
- 2001-04-27 AU AU68984/01A patent/AU783459B2/en not_active Ceased
- 2001-04-27 PL PL01358877A patent/PL358877A1/xx unknown
- 2001-04-27 SK SK1543-2002A patent/SK15432002A3/sk not_active Application Discontinuation
- 2001-04-27 AT AT01947247T patent/ATE348805T1/de not_active IP Right Cessation
- 2001-04-27 CN CNB018104762A patent/CN1286810C/zh not_active Expired - Fee Related
- 2001-04-27 NZ NZ522246A patent/NZ522246A/en unknown
- 2001-04-27 IL IL15247701A patent/IL152477A0/xx unknown
- 2001-04-27 MX MXPA02010627A patent/MXPA02010627A/es active IP Right Grant
- 2001-04-27 US US09/843,139 patent/US20020091124A1/en not_active Abandoned
- 2001-04-27 RU RU2002132253/04A patent/RU2002132253A/ru not_active Application Discontinuation
- 2001-04-27 AR ARP010102016A patent/AR029915A1/es not_active Application Discontinuation
- 2001-04-27 WO PCT/EP2001/004783 patent/WO2001082909A2/de active IP Right Grant
- 2001-04-27 GE GE5060A patent/GEP20063751B/en unknown
- 2001-04-27 CZ CZ20023544A patent/CZ20023544A3/cs unknown
- 2001-04-27 BR BR0110414-4A patent/BR0110414A/pt not_active IP Right Cessation
- 2001-04-27 EP EP01947247A patent/EP1276720B1/de not_active Expired - Lifetime
- 2001-04-27 JP JP2001579784A patent/JP2004501092A/ja not_active Withdrawn
-
2002
- 2002-10-24 US US10/279,123 patent/US20030158216A1/en not_active Abandoned
- 2002-10-25 NO NO20025150A patent/NO20025150L/no not_active Application Discontinuation
- 2002-10-25 IS IS6594A patent/IS6594A/is unknown
- 2002-11-25 BG BG107309A patent/BG107309A/bg unknown
- 2002-11-27 HR HR20020940A patent/HRP20020940A2/hr not_active Application Discontinuation
-
2003
- 2003-07-21 HK HK03105237.9A patent/HK1054549B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0300480A2 (hu) | 2-Acil-indol-származékok és tumorellenes szerként történő alkalmazásuk | |
| HUP0204418A2 (hu) | NHE-1 inhibitor hatású N-[(helyettesített öttagú, di- vagy triaza-, kétszeresen telítetlen gyűrű)-karbonil]-guanidin-származékok és alkalmazásuk | |
| HUP0300743A2 (hu) | Heteroarilszármazékok és alkalmazásuk gyógyszerként | |
| HUP0303729A2 (hu) | Akridinszármazékok és azok gyógyszerként történő alkalmazása és eljárás az előállításukra | |
| HUP0400554A2 (hu) | Tetrahidropiridin-származékok, előállításuk és felhasználásuk sejtburjánzás-inhibitorként | |
| YU69902A (sh) | Novi derivati piperazina | |
| HK1125577A1 (en) | Treatment of duchenne muscular dystrophy | |
| HUP0300618A2 (hu) | Adamantánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0204474A2 (hu) | 1H-imidazopiridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0400250A2 (hu) | 5-HT6 és/vagy 5-HT7 szerotonin receptorok ligandumaként alkalmazott 5-halogén-triptamin-származékok, előállításuk és alkalmazásuk gyógyszerkészítmények előállítására | |
| AP2002002535A0 (en) | Caspase inhibitors and uses thereof. | |
| DE60027648D1 (de) | Sulfonamide enthaltende indolderivate | |
| HUP0101031A2 (hu) | Biciklo[2.2.1]heptán-származékok és rokon vegyületek | |
| HUP0204405A2 (en) | Water soluble prodrugs of azole compounds | |
| HUP0002517A2 (hu) | Acil-piperazinilpirimidin-származékok, eljárás előállításukra, a vegyületeket tartalmazó gyógyászati készítmények és gyógyszerként való alkalmazásuk | |
| HUP0402510A2 (hu) | Nociceptin analógok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0300677A2 (hu) | Újfajta indolszármazékok, és azok gyógyszerként történő alkalmazása és eljárás az előállításukra | |
| HUP0401949A2 (hu) | 4-Imidazolin-2-on-származékok | |
| HUP0204360A2 (en) | Substituted norbornylamino derivatives, method for the production thereof, use thereof as a medicament and medicaments containing said compounds | |
| MXPA05009282A (es) | Derivados de anilina sustituidos. | |
| HUP0101733A2 (hu) | Szulfonil dipeptideket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HK1047586A1 (en) | Process for the preparation of pyrazoloÄ1,5-bÜpyridazine derivatives. | |
| IL110041A0 (en) | Carbocyclic nucleoside agents useful, as selective inhibitors of proinflammatory cytokines | |
| HUP9901988A2 (hu) | 2,2'-bi(1H-pirrol)-vegyületet tartalmazó szinergetikus immunszuppresszív készítmény | |
| IL179029A0 (en) | New piperazine derivatives of dialkyl oxindoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |